TrialNature cancer2022

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.

Joshua J Gruber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.